Biomics Biotechnologies (Nantong) Co., Ltd. ( "Biomics" ) is Asia's leading RNAi therapeutical technologies company. It is one of the world's very few companies having the combined platform of full-sites siRNA library, drug targets screening and identification, siRNA structure modification and drug delivery systems.

The company was founded by Dr. York Zhu, an American scientist, in February 2006. So far the company has built a siRNA drug R&D center and a drug delivery lab in the Silicon Valley and Seattle respectively, together with a phase I R&D base in the National Economic and Technological Development Area in Nantong, China (about ~ 2hrs driving distance to Shanghai).

Since its inception in 2006, Biomics has proudly established GeneTargetTM full-sites siRNA library construction technical platform. The company's competitive edge and core value lie in its continuing development of siRNA drug innovation. With GeneTargetTM full-sites siRNA library of high-throughput construction technology, the company can efficiently find the precise gene's silencing targets. By using its world-class proprietary drug delivery system development platform and the siRNA molecular structure modification technologies, the company is playing a leading role in developing new siRNA drugs.

Biomics' development strategy is to rely on the siRNA drug innovation as its core competence, attract a number of elite R&D and management professionals to conduct the screening and identification of gene silencing siRNA drug targets, to develop siRNA drugs and drug delivery systems, so as to achieve the goal of being a first-class RNA interference (RNAi) treatment developer in the international arena.